Skip to content
Checked.be
Complete company report
Generated 18-08-2026
Active BE 0724.569.610Public limited company

Sagitta Biotech

Avenue Hippocrate 5 ·4000 Liège, Belgium· 7 yrs active
Sector: Speur- en ontwikkelingswerk op biotechnologisch gebied (72101)
Conclusion Checked

The computed 12-month bankruptcy probability of Sagitta Biotech is 0.7% (low). The company has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.

Based on State Gazette and CBE data.
Key figures
Active 7 yrs
Board 2
Locations 1
Publications 5
Bankruptcy probability (12 mo) Checked model v1 · free
0.7% Low
0%0,5%1,5%4%10%≥25%
Young company +Lower-failure-rate sector −Lower-risk legal form −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Risk Assessment rule-based
0 / 100
Low risk
Trust signals 2 signals
More than 3 years active
Founded in 2019, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags0 events
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Financial overview7 NBB filings
Financials being processed
NBB has 7 filing(s) on record for this company, latest fiscal year 2025 (micro). The annual accounts are being processed.
Filings on record
Fiscal year Type Filed Reference
31-12-2025 micro 26-03-2026 2026-00064529
31-12-2024 micro 31-03-2025 2025-00060600
31-12-2023 micro 03-04-2024 2024-00057308
31-12-2022 micro 21-03-2023 2023-00044166
31-12-2021 micro 19-04-2022 2022-20005888
31-12-2020 micro 18-03-2021 2021-07900155
31-12-2019 micro 24-03-2020 2020-07400376
Directors & mandates 3 directors
Current directors & mandates
  • ALLAER Didier
    Director
    State Gazette act 23305887 (18-01-2023)
    Current
    18-01-2023 → present
  • NOSHAQ PARTNERSLegal entity
    Director· perm. rep.: SCHYNTS Frédéric
    State Gazette act 23305887 (18-01-2023)
    Current
    18-01-2023 → present
Former directors (1)
  • NEMESIS CONSULTINGLegal entity
    Director· perm. rep.: DAMIEN Benjamin
    State Gazette act 23305887 (18-01-2023)
    Former
    - → 18-01-2023
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Legal Structure
NACE primary Speur- en ontwikkelingswerk op biotechnologisch gebied(72101)
Legal form Public limited company(014)
Incorporation04-04-2019
StatusActive
Postal code4000
Connections & network 2 connected companies
Group structure
NOSHAQ PARTNERS
Sits on the board · 61 subsidiaries · 1 location
Control→
Network connections
→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.
Ownership & control 1 parties
Control over this companysits on this company's board1
NOSHAQ PARTNERS
61 subsidiaries · 1 location
controls
Sagitta BiotechBE 0724.569.610

Each band states what its claims rest on. A board seat is influence over the board, not ownership. Court mandates (receiver, interim administrator) and liquidation mandates do not link companies and are therefore absent here; they belong under Directors & mandates.

Establishment units 1 location
Sagitta Biotech
Avenue Pré-Aily 10, 4031 LiègeSpeur- en ontwikkelingswerk op biotechnologisch gebied
since 20192.350.560.319
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Real-estate footprint Source: CBE × cadastre

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Wallonia 2 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
62002C0005/00X010 Wallonia 1,679 m² - -
62826D0504/00C003 Wallonia 955 m² 1 · 540 m² 21.4 m · 7 fl.
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates 12 events

A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.

2026
23-04-2026
State Gazette act Capital & shares
Geoffrey GAUTHY
26-03-2026
NBB filing Annual accounts filed
fiscal year 2025 · micro
2025
01-08-2025
State Gazette act Capital & shares
v3.2
31-03-2025
NBB filing Annual accounts filed
fiscal year 2024 · micro
12-03-2025
State Gazette act Capital & shares
v3.2
2024
03-04-2024
NBB filing Annual accounts filed
fiscal year 2023 · micro
2023
21-03-2023
NBB filing Annual accounts filed
fiscal year 2022 · micro
18-01-2023
State Gazette act Capital & shares
v3.2
2022
19-04-2022
NBB filing Annual accounts filed
fiscal year 2021 · micro
2021
18-03-2021
NBB filing Annual accounts filed
fiscal year 2020 · micro
2020
24-03-2020
NBB filing Annual accounts filed
fiscal year 2019 · micro
2019
08-04-2019
State Gazette act Incorporation
oprichting
Belgian State Gazette reading coverage 0 of 5 acts read

We know of 5 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.

Belgisch Staatsblad, acts 5 acts
Capital history · 4
23-04-2026
Capital change
01-08-2025
v3.2
12-03-2025
v3.2
18-01-2023
v3.2
All acts · 5 updated 3 months ago
2026
23-04-2026 Capital decrease of €750,000 to €1,020,000 Capital & shares·Geoffrey GAUTHY
  • €1.770.000 → €1.020.000
  • 2 kapitaalbewegingen in deze akte
Notary: Geoffrey GAUTHY · Herstal
Technical details 
{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 1770000.0,
      "delta_eur": 500000.0,
      "before_eur": 1270000.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": "B",
        "n_new_shares": 142,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 3521.13
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 500000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "capital_decrease",
      "after_eur": 1020000.0,
      "delta_eur": -750000.0,
      "before_eur": 1770000.0,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": "loss_absorption",
      "contribution_type": "reserves_incorporation",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Geoffrey GAUTHY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Herstal",
    "is_associated": false
  },
  "act_meta": {
    "language": "mixed",
    "pub_date": "2026-04-23",
    "filing_date": "2026-04-21",
    "act_kind_objet": "Objet de l\u0027acte : SIEGE SOCIAL, CAPITAL, ACTIONS"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2026-04-21",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": {
    "waived": true,
    "firm_kbo": null,
    "firm_name": null,
    "ibr_number": null,
    "mission_type": null,
    "individual_name": null
  },
  "subject_company": {
    "kbo": "0724.569.610",
    "name_full": "SAGITTA BIOTECH",
    "legal_form": "Soci\u00E9t\u00E9 anonyme",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": null,
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "expedition de l\u2019assembl\u00E9e comprenant les procurations et le rapport du CA",
    "la coordination des statuts"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 114,
      "class_name": "A",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    },
    {
      "n_shares": 482,
      "class_name": "B",
      "capital_share_eur": null,
      "voting_rights_per_share": null
    }
  ]
}
2025
01-08-2025 Capital increase of €300,000 to €1,270,000 Capital & shares
  • €970.000 → €1.270.000
Summary: v3.2
Technical details 
{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 300000.0,
      "currency": "EUR",
      "after_eur": 1270000.0,
      "delta_eur": 300000.0,
      "before_eur": 970000.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2025-07-30",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de 300.000,00 \u20AC pour le porter de 970.000,00 \u20AC \u00E0 1.270.000,00 \u20AC par la cr\u00E9ation de 84 actions de classe B nouvelles sans d\u00E9signation de valeur nominale, \u00E0 souscrire en num\u00E9raire au prix arrondi de 3.571,43 \u20AC par action, et \u00E0 lib\u00E9rer imm\u00E9diatement \u00E0 concurrence de la totalit\u00E9 par les souscripteurs.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0724.569.610",
    "name_full": "SAGITTA BIOTECH",
    "legal_form": "SA"
  }
}
12-03-2025 Capital increase of €300,000 to €970,000 Capital & shares
  • €670.000 → €970.000
Summary: v3.2
Technical details 
{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 300000.0,
      "currency": "EUR",
      "after_eur": 970000.0,
      "delta_eur": 300000.0,
      "before_eur": 670000.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2025-02-27",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de 300.000,00 \u20AC pour le porter de 670.000,00 \u20AC \u00E0 970.000,00 \u20AC par la cr\u00E9ation de 86 actions de classe B nouvelles sans d\u00E9signation de valeur nominale, \u00E0 souscrire en num\u00E9raire au prix arrondi de 3.488,37 \u20AC par action, et \u00E0 lib\u00E9rer imm\u00E9diatement \u00E0 concurrence de la totalit\u00E9 par les souscripteurs.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0724.569.610",
    "name_full": "SAGITTA BIOTECH",
    "legal_form": "SA"
  }
}
2023
18-01-2023 Capital increase of €650,000 to €670,000 Capital & shares
  • €20.000 → €670.000
Summary: v3.2
Technical details 
{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 650000.0,
      "currency": "EUR",
      "after_eur": 670000.0,
      "delta_eur": 650000.0,
      "before_eur": 20000.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2023-01-16",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de six cent cinquante mille euros (650.000,00 \u20AC) pour le porter de vingt mille euros (20.000,00 \u20AC) \u00E0 six cent septante mille euros (670.000,00 \u20AC) par la cr\u00E9ation de 184 actions nouvelles sans d\u00E9signation de valeur nominale, \u00E0 souscrire en num\u00E9raire au prix arrondi de 3.532,61 \u20AC par action, et \u00E0 lib\u00E9rer \u00E0 concurrence de moiti\u00E9 par les souscripteurs.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0724.569.610",
    "name_full": "SAGITTA BIOTECH",
    "legal_form": "SPRL"
  }
}
2019
08-04-2019 Incorporation of a new SNC Incorporation
Summary: oprichting
Technical details 
{
  "kind": "oprichting",
  "seat": "Place Albert Ier 5, 7170 Fayt-lez-Manage",
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "founders": [
    {
      "org": {
        "kbo": "0723.853.095",
        "name": "NEMESIS CONSULTING"
      },
      "kind": "rechtspersoon",
      "person": null,
      "share_class": "nominative",
      "partner_role": null,
      "holder_org_kbo": "0723.853.095",
      "holder_org_name": "NEMESIS CONSULTING",
      "contribution_type": "cash",
      "amount_paid_in_eur": 20000,
      "holder_person_name": null,
      "is_subscriber_only": true,
      "n_shares_subscribed": 100,
      "amount_subscribed_eur": 20000,
      "is_anonymous_silent_partner": false
    }
  ],
  "capital_eur": 20000,
  "subject_company": {
    "kbo": "0724.569.610",
    "name_full": "Sagitta Biotech",
    "legal_form": "SNC"
  },
  "initial_directors": [],
  "incorporation_date": "2019-04-04",
  "post_incorporation_mandates": []
}
Credit advice verdict per customer and amount

May this customer buy amount X on invoice? Enter the amount and the payment term. This page computes a GREEN, AMBER or RED verdict from them, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.
Company registry (CBE) Crossroads Bank
Activities
Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110
Primary activity highlighted.
Names & trade names
Legal nameFR Sagitta Biotech
Registered office
Avenue Hippocrate 5 bus GIGA
4000 Liège, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies Same sector and region · no size comparison possible · 146 of 760 with filed accounts
Abscint BE 0749.828.410 · Liège
AEXYRA BIO BE 1038.299.282 · Liège
Amyl Therapeutics BE 0758.775.372 · Liège
Apmonia Therapeutics BE 1026.581.583 · Liège
BELMA TECHNOLOGIES BE 0640.973.129 · Liège
Source: Belgian State Gazette, CBE, NBB · generated via checked.be · indicative